MH

Mark Hatcher

Senior Director, CMC Synthetic Chemistry at SpringWorks Therapeutics

Mark Hatcher has extensive work experience in the pharmaceutical industry. Mark has served in various roles at different companies throughout their career.

Mark started their career as an Intern at McNeil Nutritionals in 1998. The following year, they worked as a Chemistry Intern at ViroPharma Incorporated.

In 2007, Mark joined GlaxoSmithKline as a Principal Scientist in API process chemistry. Mark contributed to the development and implementation of new synthetic chemistry processes for complex small molecules. Mark also worked closely with early discovery teams to monitor synthetic routes and offer advice on large-scale implementation and development. Mark later became an Investigator, where they served as the Chemistry Project Leader for the development of an oncology drug candidate. Mark successfully delivered active pharmaceutical ingredients (API) to support clinical evaluation studies.

From 2014 to 2017, Mark held the position of Director of US R&D Policy and Scientific Affairs at GlaxoSmithKline. Mark was responsible for policy and advocacy activities in support of global R&D operations and future strategic initiatives.

In 2018, Mark joined Roivant Sciences as an Associate Director of API Chemistry & Engineering for a brief period before transitioning to a similar role at Urovant Sciences. Mark then became an Associate Director and later a Director of CMC Synthetic Chemistry at SpringWorks Therapeutics. In these roles, Mark oversaw drug substance development and manufacturing activities, led teams, managed activities at primary external CMO, and conducted DoE development studies and process validation.

Overall, Mark Hatcher has a diverse background and expertise in synthetic chemistry, API process chemistry, and R&D policy.

Mark Hatcher holds a Bachelor of Science degree in Chemistry from Penn State University, which they obtained from 1994 to 1999. Mark then pursued a Doctor of Philosophy (Ph.D.) in Organic Chemistry at The Johns Hopkins University from 1999 to 2005. Subsequently, from 2005 to 2007, they were a Postdoctoral Associate in Organic Chemistry at the University of North Carolina at Chapel Hill. In 2020, Mark also obtained a certification in Microsoft Teams Essential Training from LinkedIn.

Links

Previous companies

Roivant Sciences logo
ViroPharma Inc. logo

Timeline

  • Senior Director, CMC Synthetic Chemistry

    January, 2023 - present

  • Director, CMC Synthetic Chemistry

    January, 2021

  • Associate Director, CMC Synthetic Chemistry

    December, 2018

A panel showing how The Org can help with contacting the right person.